Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics

T. Motta, S. De Vincentiis, M. Marchini, N. Colombo, A. D'Alberton

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.

Original languageEnglish
Pages (from-to)440-442
Number of pages3
JournalFertility and Sterility
Volume65
Issue number2
Publication statusPublished - 1996

Fingerprint

Hyperprolactinemia
Prolactinoma
International System of Units
Serum
Hospital Outpatient Clinics
Menstruation
Amenorrhea
Therapeutics
Oral Administration
Reference Values
Outcome Assessment (Health Care)
cabergoline
Neoplasms

Keywords

  • bromocriptine
  • Cabergoline
  • macroprolactinoma
  • MRI

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. / Motta, T.; De Vincentiis, S.; Marchini, M.; Colombo, N.; D'Alberton, A.

In: Fertility and Sterility, Vol. 65, No. 2, 1996, p. 440-442.

Research output: Contribution to journalArticle

@article{7bcc908456284b52aaf42f0174aa515f,
title = "Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics",
abstract = "Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50{\%} to 85{\%} of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70{\%} reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.",
keywords = "bromocriptine, Cabergoline, macroprolactinoma, MRI",
author = "T. Motta and {De Vincentiis}, S. and M. Marchini and N. Colombo and A. D'Alberton",
year = "1996",
language = "English",
volume = "65",
pages = "440--442",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics

AU - Motta, T.

AU - De Vincentiis, S.

AU - Marchini, M.

AU - Colombo, N.

AU - D'Alberton, A.

PY - 1996

Y1 - 1996

N2 - Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.

AB - Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.

KW - bromocriptine

KW - Cabergoline

KW - macroprolactinoma

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=0030063569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030063569&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 440

EP - 442

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 2

ER -